CSIRO Australian Centre for Disease Preparedness, 5 Portarlington Rd., East Geelong, 3219, Australia.
CSIRO Manufacturing, 343 Royal Parade, Parkville, 3052, Australia.
Antiviral Res. 2020 Oct;182:104895. doi: 10.1016/j.antiviral.2020.104895. Epub 2020 Aug 1.
With the introduction of the influenza specific neuraminidase inhibitors (NAIs) in 1999, there were concerns about the emergence and spread of resistant viruses in the community setting. Surveillance and testing of community isolates for their susceptibility to the NAIs was initially carried out by the Neuraminidase Inhibitor Susceptibility Network (NISN) and has subsequently been taken on by the global WHO influenza network laboratories. During the NISN surveillance, we identified two Yamagata lineage influenza B viruses with amino acid substitutions of H134Y (B/Auckland/2/2001) or W438R (B/Yokohama/12/2005) which had slightly elevated IC values for zanamivir and/or oseltamivir, but not sufficiently to be characterized as mild outliers at the time. As it has now been well demonstrated that mixed populations can mask the true magnitude of resistance of a mutant, we re-examined both of these isolates by plaque purification to see if the true susceptibilities were being masked due to mixed populations. Results confirmed that the B/Auckland isolate contained both wild type and H134Y mutant populations, with mutant IC values > 250 nM for both oseltamivir and peramivir in the enzyme inhibition assay. The B/Yokohama isolate also contained both wild type and W438R mutant populations, the latter now demonstrating IC values > 400 nM for zanamivir, oseltamivir and peramivir. In addition, plaque purification of the B/Yokohama isolate identified viruses with other single neuraminidase substitutions H134Y, H134R, H431R, or T436P. H134R and H431R viruses had IC values > 400 nM and >250 nM respectively against all three NAIs. All changes conferred much greater resistance to peramivir than to zanamivir, and less to oseltamivir, and affected the kinetics of binding and dissociation of the NAIs. Most affected affinity (K) for the MUNANA substrate, but some had decreased while others had increased affinity. Despite resistance in the enzyme assay, no reduced susceptibility was seen in plaque reduction assays in MDCK cells for any of the mutant viruses. None of these substitutions was in the active site. Modelling suggests that these substitutions affect the 150 and 430-loop regions described for influenza A NAs, suggesting they may also be important for substrate and inhibitor binding for influenza B NAs.
随着 1999 年流感特异性神经氨酸酶抑制剂(NAI)的引入,人们担心社区环境中耐药病毒的出现和传播。最初,社区分离株对 NAI 的敏感性由神经氨酸酶抑制剂敏感性网络(NISN)进行监测和检测,随后由全球世卫组织流感网络实验室承担。在 NISN 监测期间,我们发现了两株带有 H134Y(B/Auckland/2/2001)或 W438R(B/Yokohama/12/2005)氨基酸取代的 Yamagata 谱系流感 B 病毒,它们对扎那米韦和/或奥司他韦的 IC 值略有升高,但不足以在当时被认为是温和的异常值。由于现在已经充分证明,混合种群可以掩盖突变体耐药的真实程度,因此我们通过斑块纯化重新检查了这两种分离株,以确定是否由于混合种群而掩盖了真实的敏感性。结果证实,B/Auckland 分离株既包含野生型,也包含 H134Y 突变型,在酶抑制测定中,奥司他韦和帕拉米韦的突变体 IC 值均>250 nM。B/Yokohama 分离株也包含野生型和 W438R 突变型,后者现在对扎那米韦、奥司他韦和帕拉米韦的 IC 值>400 nM。此外,B/Yokohama 分离株的斑块纯化鉴定出具有其他单个神经氨酸酶取代 H134Y、H134R、H431R 或 T436P 的病毒。H134R 和 H431R 病毒对所有三种 NAI 的 IC 值均>400 nM 和>250 nM。所有这些变化都使对帕拉米韦的耐药性大大增加,而对扎那米韦的耐药性则较低,对奥司他韦的耐药性也较低,并且影响了 NAI 的结合和解离动力学。大多数影响对 MUNANA 底物的亲和力(K),但有些降低,而有些增加。尽管在酶测定中存在耐药性,但在 MDCK 细胞中的斑块减少测定中,没有观察到任何突变病毒的敏感性降低。这些取代均不在活性部位。建模表明,这些取代影响了描述流感 A NAs 的 150 和 430 环区,表明它们对流感 B NAs 的底物和抑制剂结合也可能很重要。